John Marcum M.D. – Childrens Hospital Los Angeles

Recipient: John Marcum M.D. – Childrens Hospital Los Angeles
Product: Investigational device
Date: 1/27/05

Records relating to correspondence with the IRB and sponsor, including required reports, are not all complete. For instance, there is no correspondence demonstrating that the sponsor and IRB were notified of all adverse events and serious adverse events, including the nine infections and four deaths. The sponsor and IRB were not notified of the decision to deviate from or modify the approved protocol. For example, the data was not collected per protocol and the number of subjects was modified. It was also noted in the inspection report that the actual protocol version used for the conduct of the study (dated 10/02/03) was the version that was last submitted and not the version approved and returned by the IRB. This version was an electronic copy maintained in the computer and was not printed, copied and distributed to all participating clinical investigators. In your response, you have stated that the sponsor and IRB will be notified and correspondence documented; we find these responses acceptable.

Records of each subject’s case history are not all accurate. Specifically, several Case Report Forms had data times and results which did not match raw data time and results, particularly for the _____. The FDA investigators noted the Case Report Forms in general were incomplete with various cross-outs and changes by multiple authors, and an occassional white-out. In addition, one informed consent form was noted to be missing _____. In your response you included a copy of corrected data records and you state that system problems with the computerized medical record are being addressed, that copies of all raw data will be made and/or attached to the Case Report Form, and that a time range will be provided if there will is a variation in the timing of data collection. We find these responses acceptable.

Issuer: Center for Devices and Radiological Health (CDRH)

About the author

Amy enjoys researching and writing about developments in medical technology and how that intersects with US law. She received her J.D. from the University of Florida Levin College of Law in 2020 and now works as a Regulatory Associate for SoftwareCPR®, a general-purpose regulatory consulting firm that is recognized globally for their expertise with standards and national regulations pertaining to medical device, mobile medical app, and HealthIT software.

SoftwareCPR Training Courses:

IEC 62304 and other emerging standards for Medical Device and HealthIT Software

Our flagship course for preparing regulatory, quality, engineering, operations, and others for the activities and documentation expected for IEC 62304 conformance and for FDA expectations. The goal is to educate on the intent and purpose so that the participants are able to make informed decisions in the future.  Focus is not simply what the standard says, but what is meant and discuss examples and approaches one might implement to comply.  Special deep discount pricing available to FDA attendees and other regulators.

3-days onsite with group exercises, quizzes, examples, Q&A.

Instructor: Brian Pate

Next public offering:  TBD

Email training@softwarecpr.com to request a special pre-registration discount.  Limited number of pre-registration coupons.

Registration Link:

TBD

 


 

Being Agile & Yet Compliant (Public or Private)

Our SoftwareCPR unique approach to incorporating agile and lean engineering to your medical device software process training course is now open for scheduling!

  • Agile principles that align well with medical
  • Backlog management
  • Agile risk management
  • Incremental and iterative software development lifecycle management
  •  Frequent release management
  • And more!

2-days onsite (4 days virtual) with group exercises, quizzes, examples, Q&A.

Instructors: Mike Russell, Ron Baerg

Next public offering: March 7 & 28, 2024

Virtual via Zoom

Registration Link:

Register Now

 


 

Medical Device Cybersecurity (Public or Private)

This course takes a deep dive into the US FDA expectations for cybersecurity activities in the product development process with central focus on the cybersecurity risk analysis process. Overall approach will be tied to relevant standards and FDA guidance documentation. The course will follow the ISO 14971:2019 framework for overall structure but utilize IEC 62304, IEC 81001-5-1, and AAMI TIR57 for specific details regarding cybersecurity planning, risk characterization, threat modeling, and control strategies.

2-days onsite with group exercises, quizzes, examples, Q&A.

Instructor: Dr Peter Rech, 2nd instructor (optional)

Next public offering:  TBD

Corporate Office

15148 Springview St.
Tampa, FL 33624
USA
+1-781-721-2921
Partners located in the US (CA, FL, MA, MN, TX) and Canada.